These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 18160670)

  • 81. Laboratory detection of JAK2V617F in human myeloproliferative neoplasms.
    Kui JS; Espinal-Witter R; Wang YL
    Methods Mol Biol; 2013; 999():41-57. PubMed ID: 23666689
    [TBL] [Abstract][Full Text] [Related]  

  • 82. An inhibitor of Janus kinase 2 prevents polycythemia in mice.
    Mathur A; Mo JR; Kraus M; O'Hare E; Sinclair P; Young J; Zhao S; Wang Y; Kopinja J; Qu X; Reilly J; Walker D; Xu L; Aleksandrowicz D; Marshall G; Scott ML; Kohl NE; Bachman E
    Biochem Pharmacol; 2009 Aug; 78(4):382-9. PubMed ID: 19413997
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
    Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED
    Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768
    [TBL] [Abstract][Full Text] [Related]  

  • 84. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
    Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Reemergence of JAK2 V617F clone heralds extramedullary leukemia relapse after BMT for transformed essential thrombocytosis.
    Au WY; Fung A; Lie AK; Lam KY; Lam CC; Kwong YL
    Ann Hematol; 2007 Feb; 86(2):145-7. PubMed ID: 17111143
    [No Abstract]   [Full Text] [Related]  

  • 86. The cell cycle regulator CDC25A is a target for JAK2V617F oncogene.
    Gautier EF; Picard M; Laurent C; Marty C; Villeval JL; Demur C; Delhommeau F; Hexner E; Giraudier S; Bonnevialle N; Ducommun B; Récher C; Laurent G; Manenti S; Mansat-De Mas V
    Blood; 2012 Feb; 119(5):1190-9. PubMed ID: 22065597
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.
    Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM
    J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Aberrant signal transduction pathways in myeloproliferative neoplasms.
    Kota J; Caceres N; Constantinescu SN
    Leukemia; 2008 Oct; 22(10):1828-40. PubMed ID: 18769448
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model.
    Kubovcakova L; Lundberg P; Grisouard J; Hao-Shen H; Romanet V; Andraos R; Murakami M; Dirnhofer S; Wagner KU; Radimerski T; Skoda RC
    Blood; 2013 Feb; 121(7):1188-99. PubMed ID: 23264594
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
    Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
    Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.
    Stein BL; Williams DM; Rogers O; Isaacs MA; Spivak JL; Moliterno AR
    Exp Hematol; 2011 Jan; 39(1):95-101. PubMed ID: 20888389
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
    Wernig G; Mercher T; Okabe R; Levine RL; Lee BH; Gilliland DG
    Blood; 2006 Jun; 107(11):4274-81. PubMed ID: 16478879
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Examining the Frequency of the
    Nasseri M; Keyfi F; Rahbarian R; Rajabian M; Abbaszadegan MR
    Rep Biochem Mol Biol; 2020 Jul; 9(2):188-192. PubMed ID: 33178868
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts.
    Zhou J; Ye Y; Zeng S; Zhou Y; Mao Z; Song X; Ying B; Lu X; Jiang H; Wang L
    PLoS One; 2013; 8(2):e57856. PubMed ID: 23469088
    [TBL] [Abstract][Full Text] [Related]  

  • 95. SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm.
    Yang Y; Abbas S; Sayem MA; Dutta A; Mohi G
    Blood Cancer J; 2023 Nov; 13(1):171. PubMed ID: 38012156
    [TBL] [Abstract][Full Text] [Related]  

  • 96. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.
    Plo I; Nakatake M; Malivert L; de Villartay JP; Giraudier S; Villeval JL; Wiesmuller L; Vainchenker W
    Blood; 2008 Aug; 112(4):1402-12. PubMed ID: 18515659
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.
    James C; Mazurier F; Dupont S; Chaligne R; Lamrissi-Garcia I; Tulliez M; Lippert E; Mahon FX; Pasquet JM; Etienne G; Delhommeau F; Giraudier S; Vainchenker W; de Verneuil H
    Blood; 2008 Sep; 112(6):2429-38. PubMed ID: 18612101
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
    Marchetti M; Castoldi E; Spronk HM; van Oerle R; Balducci D; Barbui T; Rosing J; Ten Cate H; Falanga A
    Blood; 2008 Nov; 112(10):4061-8. PubMed ID: 18768782
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.
    Jamieson CH; Gotlib J; Durocher JA; Chao MP; Mariappan MR; Lay M; Jones C; Zehnder JL; Lilleberg SL; Weissman IL
    Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6224-9. PubMed ID: 16603627
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Platelet Dysfunction and Thrombosis in JAK2
    Matsuura S; Thompson CR; Belghasem ME; Bekendam RH; Piasecki A; Leiva O; Ray A; Italiano J; Yang M; Merill-Skoloff G; Chitalia VC; Flaumenhaft R; Ravid K
    Arterioscler Thromb Vasc Biol; 2020 Oct; 40(10):e262-e272. PubMed ID: 32814440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.